Skin Reactions ‘Frequent’ With Mavenclad, Real-world Study Finds

Skin Reactions ‘Frequent’ With Mavenclad, Real-world Study Finds

300415

Skin Reactions ‘Frequent’ With Mavenclad, Real-world Study Finds

Skin reactions are common among relapsing-remitting multiple sclerosis (RRMS) patients being treated with oral Mavenclad (cladribine), affecting about one-third of the people evaluated in a real-world study in Germany. These findings suggest the need for careful clinical surveillance to rapidly diagnose and possibly treat skin problems stemming from Mavenclad’s use, its researchers noted. The study, “Skin reactions in patients with multiple sclerosis receiving cladribine treatment,” was published in Neuroimmunology & Neuroinflammation. Mavenclad, an oral disease-modifying therapy developed…

You must be logged in to read/download the full post.